Dataset from A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta 1a (Rebif®) in Patients With Relapsing Remitting Multiple Sclerosis Who Have Relapsed On Therapy

The purpose of this study was to establish the efficacy and safety of two different doses of
alemtuzumab (Lemtrada™) as a treatment for relapsing-remitting multiple sclerosis (MS), in
comparison with subcutaneous interferon beta-1a (Rebif®). The study enrolled participants who
had received an adequate trial of disease-modifying therapies but experienced at least 1
relapse during prior treatment, and who met a minimum severity of disease as measured by
magnetic resonance imaging (MRI). Participants had monthly laboratory tests and comprehensive
testing every 3 months.